Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Dual mechanism of mangiferin protection against iron-induced damage to 2-deoxyribose and ascorbate oxidation
Author: Pardo-Andreu, GL
Delgado, R
Nunez-Selles, AJ
Vercesi, AE
Abstract: We studied mangiferin effects on the degradation of 2-deoxyribose induced by Fe(III)-EDTA/citrate plus ascorbate, in relation to ascorbate oxidation (measured at 265 nm). Results revealed that mangiferin was equally effective in preventing degradation of both 15 and 1.5 mM 2-deoxyribose. At a fixed Fe(III) concentration, increasing the concentration of ligands (either EDTA or citrate) caused a significant reduction in the protective effects of mangiferin. Interestingly, mangiferin strongly stimulated Fe(III)-EDTA ascorbate oxidation, but inhibited it when citrate was used as iron co-chelator. Mangiferin stimulated O-2 consumption due to Fe(II) (formed by Fe(III) ascorbate reduction) autoxidation when the metal ligand was EDTA, but inhibited it when citrate was used. These results suggest that mangiferin removes iron from citrate, but not from EDTA, forming an iron-mangiferin complex that cannot induce ascorbate oxidation effectively, thus inhibiting iron-mediated oxyradical formation. Taken together, these results indicate that mangiferin works mainly by a mechanism different from the classical hydroxyl radical scavengers, keeping iron in its ferric form, by complexing Fe(III), or stimulating Fe(11) autoxidation. (c) 2005 Elsevier Ltd. All rights reserved.
Subject: mangiferin
iron chelation
Country: Inglaterra
Editor: Academic Press Ltd Elsevier Science Ltd
Citation: Pharmacological Research. Academic Press Ltd Elsevier Science Ltd, v. 53, n. 3, n. 253, n. 260, 2006.
Rights: fechado
Identifier DOI: 10.1016/j.phrs.2005.06.006
Date Issue: 2006
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000236072800008.pdf395.03 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.